DPDoctor's PassportEducation
Educational draft · awaiting clinical reviewThe full textbook explains uncertainty but does not replace live national or local guidance, specialist advice, or current prescribing information.
Full textbookMLAMSRAFoundationMRCS

Wilson disease

Recognise hepatic and neuropsychiatric Wilson disease, combine imperfect copper tests and deliver lifelong specialist decoppering without losing an acute transplant window.

!
Time-critical presentation

Acute liver failure in a child or young adult, especially with Coombs-negative haemolysis, disproportionate hyperbilirubinaemia, kidney injury or unexpectedly low alkaline phosphatase, is Wilson disease until urgently assessed. Contact a specialist liver-transplant centre immediately; diagnostic sampling and prognostic assessment run in parallel and chelation must not delay listing. New encephalopathy, rapidly worsening coagulopathy, hypoglycaemia or lactate is time critical. Marked neurological deterioration, dysphagia, aspiration, dystonic crisis, suicidality or severe cytopenia during treatment also requires urgent specialist review rather than abrupt unsupervised drug cessation.

Open the sections you need. The overview is shown first.
01OverviewDefinition, clinical context and the essential points that orientate the chapter.

ATP7B is required for hepatocytes to export excess copper into bile. When both alleles are pathogenic, copper accumulates and eventually spills into blood and extrahepatic tissues. Liver manifestations range from steatosis or incidental transaminase elevation through chronic hepatitis and cirrhosis to fulminant failure. Neurological disease can produce tremor, dystonia, dysarthria, parkinsonism, ataxia or drooling, while psychiatric change includes depression, disinhibition, cognitive decline or psychosis. The breadth of presentation and lack of one definitive screening result account for diagnostic delay.

A structured assessment uses the Leipzig concept but preserves clinical judgement. Low caeruloplasmin, Kayser-Fleischer rings, increased twenty-four-hour urinary copper, ATP7B variants and increased hepatic copper each add evidence. Total serum copper can be low because caeruloplasmin-bound copper falls, even while toxic exchangeable copper is high. Acute liver failure distorts several tests. Genetic analysis may find two pathogenic variants but can be inconclusive; quantitative hepatic copper is useful when uncertainty remains, although sampling variation and cholestasis can mislead.

Treatment aims for negative copper balance initially and stable safe control thereafter. Chelators increase urinary excretion; zinc reduces intestinal absorption. The exact choice depends on hepatic versus neurological disease, prior intolerance, pregnancy, age, adherence and commissioned formulations. D-penicillamine and trientine need empty-stomach spacing, and trientine salts have different elemental drug expression, so pharmacy-led switching is essential. Liver transplantation is curative for the hepatic metabolic defect in acute failure or end-stage cirrhosis but does not make diagnostic delay acceptable in neurologically affected patients.

Key points

  • Wilson disease is an autosomal recessive ATP7B disorder that impairs biliary copper excretion and copper incorporation into caeruloplasmin.
  • Copper accumulates first in liver and later brain, cornea, kidney and other tissues, producing hepatic, neurological, psychiatric, ophthalmic and haemolytic phenotypes.
  • Presentation is most common in younger people but an arbitrary age cut-off can miss later disease.
  • No single result confirms or excludes Wilson disease: caeruloplasmin, slit-lamp examination, urinary copper, genetics and sometimes liver copper must be integrated.
  • Caeruloplasmin can be normal during inflammation or pregnancy and low with other liver disease, malnutrition, protein loss or heterozygosity.
  • Kayser-Fleischer rings are common in neurological disease but may be absent in isolated hepatic presentation and require an experienced slit-lamp examination.
  • Acute Wilson liver failure may show severe Coombs-negative haemolysis and relatively low ALP against marked bilirubin; immediate transplant assessment takes precedence over a complete Leipzig score.
  • D-penicillamine, trientine and zinc act differently and are not casually interchangeable; therapy is chosen and monitored by a specialist Wilson service.
  • Neurological symptoms can worsen paradoxically when chelation begins, so dose escalation, swallowing and functional review must be planned.
  • Treatment is lifelong, including in asymptomatic relatives; non-adherence can cause irreversible hepatic or neurological relapse.
02AetiologyUnderlying causes, associations and risk factors, with why each one matters.
01

Biallelic ATP7B variants

Wilson disease is autosomal recessive; pathogenic variants impair a hepatocyte copper-transporting ATPase, with substantial genotype and phenotype variation.

02

Sibling and family risk

Full siblings have an important inherited risk and require genetics-led testing rather than waiting for symptoms or abnormal routine liver tests.

03

Variable host expression

Modifier genes, copper exposure and other incompletely understood factors influence whether hepatic, neurological, psychiatric or mixed disease appears first.

03PathophysiologyThe causal sequence from the underlying abnormality to symptoms and harm.
  1. 1
    Impaired biliary copper excretion

    Defective ATP7B prevents normal copper export into bile and reduces incorporation into functional caeruloplasmin in hepatocytes.

  2. 2
    Hepatic copper accumulation

    Copper builds within hepatocytes, generating oxidative injury, steatosis, inflammation, fibrosis or abrupt massive necrosis with ongoing exposure.

  3. 3
    Systemic copper release

    Once hepatic storage is exceeded, circulating copper deposits in brain, cornea, kidney and red cells, causing neurological, ophthalmic, renal and haemolytic features.

04Clinical features and red flagsSymptoms, examination findings, patterns of presentation and time-critical warnings.
Hepatic Wilson phenotype

Unexplained steatosis, hepatitis, jaundice, portal hypertension or cirrhosis occurs in a child, adolescent or adult without a convincing common cause.

Neurological Wilson phenotypeRed flag

New tremor, dystonia, dysarthria, drooling, parkinsonism, incoordination or handwriting change develops alongside subtle liver abnormality or psychiatric change.

Psychiatric or cognitive presentationRed flag

Personality change, depression, impulsivity, falling educational performance or psychosis precedes obvious movement disorder and should prompt neurological and hepatic examination.

Acute haemolytic liver failureRed flag

Rapid jaundice, coagulopathy, kidney injury and Coombs-negative intravascular haemolysis occur with a bilirubin rise disproportionate to alkaline phosphatase.

Ophthalmic copper deposition

A brown-green peripheral corneal ring seen by an experienced slit-lamp examiner strongly supports Wilson disease, especially with neurological manifestations.

Treated relapse or overtreatmentRed flag

Rising liver tests, recurrent movement symptoms or urinary copper change can reflect non-adherence, inadequate control or excessive decoppering and requires specialist interpretation.

05InvestigationsWhat to request, why it matters and how to interpret it.
Investigation order

Read from the initial assessment onwards. Tests may run in parallel in urgent care; first-line, preferred, confirmatory, definitive and gold-standard labels appear only when the chapter explicitly states them.

  1. 01
    Serum caeruloplasminFirst step
    Why
    Provide one biochemical component of the diagnostic score.
    Interpretation and limitations
    A low value supports Wilson disease but is non-specific, while a normal acute-phase-influenced result does not exclude it. Interpret with the laboratory method, inflammation, pregnancy and protein status.
  2. 02
    Slit-lamp corneal examination
    Why
    Detect Kayser-Fleischer rings deposited in Descemet membrane.
    Interpretation and limitations
    A specialist-positive result strongly supports disease. Absence is common enough in purely hepatic cases that it cannot close the work-up.
  3. 03
    Twenty-four-hour urinary copper
    Why
    Measure non-caeruloplasmin copper excretion before and during therapy.
    Interpretation and limitations
    Elevation supports untreated disease, but incomplete collection, acute hepatitis and cholestasis affect values. During treatment, interpret differently for a chelator versus zinc and alongside adherence and total copper status.
  4. 04
    ATP7B genomic analysis
    Why
    Identify biallelic pathogenic variants and support family testing.
    Interpretation and limitations
    Two convincing variants establish genetic support, but one or no variant does not always exclude disease because coverage and variant interpretation are incomplete. Use the current NHS genomic pathway.
  5. 05
    Quantitative hepatic copper
    Why
    Resolve persistent diagnostic uncertainty and assess tissue accumulation.
    Interpretation and limitations
    Raised dry-weight copper supports Wilson disease but cholestasis can elevate it and heterogeneous deposition can yield false-low samples. Obtain adequate tissue by the safest route and retain a portion appropriately.
  6. 06
    Haemolysis and acute liver failure panel
    Why
    Identify the fulminant Wilson pattern and organ consequences.
    Interpretation and limitations
    Request full blood count, film, reticulocytes, LDH, haptoglobin, direct antiglobulin test, INR, glucose, lactate and renal profile. Coombs-negative haemolysis with failure accelerates transplant referral.
  7. 07
    Neurological and brain MRI assessment
    Why
    Document functional phenotype and structural involvement.
    Interpretation and limitations
    Basal ganglia, thalamic or brainstem signal change can support neurological disease but a normal scan does not exclude early symptoms. Record speech, swallowing, gait and a consistent clinical scale.
  8. 08
    Leipzig diagnostic score
    Why
    Integrate copper, eye, neurological, genetic and histological evidence.
    Interpretation and limitations
    Use as a transparent aid, not a gatekeeper in acute failure. Borderline scores require expert reassessment, repeat sampling or hepatic copper rather than dismissal.
06Differential diagnosisRealistic alternatives and the features that help distinguish them.
01

Autoimmune, viral or drug-induced hepatitis

Serology, immunoglobulins and exposure history identify common hepatocellular alternatives, but acute Wilson disease can mimic autoimmune hepatitis.

02

Other causes of haemolysis

Coombs testing, blood film and clinical context distinguish copper-mediated non-immune haemolysis from autoimmune, membrane or enzyme disorders.

03

Primary neurological or psychiatric disease

Movement disorder, dysarthria or behavioural change in a younger person with liver abnormalities should prompt integrated copper assessment rather than isolated psychiatric labelling.

07ManagementImmediate care, first-line treatment, alternatives and escalation.
01Diagnostic integrationCombine evidence rather than trusting one copper testFirst stepUnexplained liver disease or compatible movement and psychiatric features raise Wilson disease.
  1. 1Assess synthetic failure and haemolysis immediately and involve a transplant centre at once if coagulopathy or encephalopathy is present.
  2. 2Obtain caeruloplasmin, slit-lamp examination, timed urinary copper and ATP7B testing while excluding viral, autoimmune, drug and other metabolic causes.
  3. 3Use the Leipzig framework to expose concordant and discordant findings and involve a specialist Wilson service before concluding a borderline case.
  4. 4Arrange quantitative hepatic copper or further expert genetic interpretation when uncertainty remains and the result will change lifelong treatment.
02Acute failureMove directly toward transplantationWilson disease is suspected during acute liver failure or rapidly progressive haemolytic hepatitis.
  1. 1Stabilise airway, glucose, circulation, kidney and cerebral risk in a liver critical-care environment and send diagnostic samples before blood products where feasible.
  2. 2Discuss transfer and listing immediately with a transplant centre and calculate the locally used Wilson acute-failure prognostic assessment serially.
  3. 3DefinitiveUse renal replacement, plasma exchange or another bridge only under transplant-centre direction and never as a reason to postpone definitive listing.
  4. 4Screen siblings urgently but separately, with asymptomatic treatment initiated only through specialist confirmation and counselling.
03Long-term decopperingChoose and titrate a sustainable lifelong regimenWilson disease is confirmed without a current transplant emergency.
  1. 1Define hepatic and neurological burden, swallowing, pregnancy plans, kidney function, prior reactions and the practical ability to take medicines away from food.
  2. 2Select D-penicillamine, a specific trientine formulation or zinc through a specialist service and introduce cautiously when neurological deterioration is a concern.
  3. 3Monitor clinical state, liver tests, blood count, urinalysis and copper balance, changing dose only after distinguishing non-adherence, undertreatment and overtreatment.
  4. 4Provide written interaction and missed-dose advice and reinforce that symptom resolution does not permit cessation of therapy.
04Family and life eventsProtect relatives, pregnancy and transitionsA diagnosis has implications for siblings, offspring or a change in life stage.
  1. 1Offer first-degree relatives clinical and genetic assessment through the NHS pathway, using targeted family variants when informative.
  2. 2Treat confirmed presymptomatic disease in a specialist centre and avoid using one normal caeruloplasmin to reassure a sibling.
  3. 3Plan pregnancy jointly with hepatology, obstetric medicine and pharmacy, generally maintaining carefully monitored anti-copper therapy rather than stopping abruptly.
  4. 4Use structured paediatric-to-adult transition and named pharmacy ownership so formulation substitutions, supply gaps and adherence deterioration are prevented.
Key medicines and prescribing safety3 treatments · regimens, roles and cautions
First-line copper chelation for selected hepatic or asymptomatic disease and an established lifelong option when effective and tolerated.

D-penicillamine

A Wilson specialist selects and gradually titrates the product-specific BNF or SmPC regimen to achieve negative copper balance, then reduces to the minimum effective maintenance dose; administration is separated from food and relevant supplements.

Monitor full blood count, urinalysis or protein, renal and liver function and neurological state. Rash, fever, cytopenia, proteinuria, autoimmune toxicity and paradoxical neurological worsening require urgent review; pyridoxine need and pregnancy dosing are specialist decisions.

Chelates copper for urinary excretion when D-penicillamine is unsuitable, with a distinct licensed formulation and dose expression.

Trientine tetrahydrochloride, Cuprior

For adults intolerant to D-penicillamine, the current SmPC recommends 450–975 mg daily in two to four divided doses, starting at the lower end and adjusting to response under a Wilson specialist.

Take on an empty stomach and separate from iron or zinc. Trientine salts and strengths are not milligram-for-milligram interchangeable; any switch needs pharmacy and specialist conversion. Monitor copper balance, iron deficiency, blood count, liver status and possible neurological worsening.

Induces enterocyte metallothionein and reduces intestinal copper absorption, often for presymptomatic or maintenance treatment in selected patients.

Zinc acetate

The current Wilzin adult regimen is 50 mg three times daily on an empty stomach, adjusted by therapeutic copper monitoring; its role and any combination with a chelator are determined by an experienced service.

Food markedly reduces absorption and gastrointestinal intolerance is common. Separate from chelators, monitor urinary copper and zinc, and avoid assuming low urinary copper always means excellent control because overtreatment and non-adherence differ.

08ComplicationsImportant consequences, why they occur and why they matter clinically.
01

Acute liver failure with haemolysis

Rapid hepatocyte necrosis releases copper, causing Coombs-negative haemolysis, kidney injury, coagulopathy and an urgent transplant window.

02

Cirrhosis and portal hypertension

Chronic hepatic accumulation produces fibrosis, ascites, varices and decompensation even when neurological symptoms dominate at diagnosis.

03

Irreversible neurological and renal injury

Delayed treatment can leave persistent tremor, dystonia, dysarthria, psychiatric disability, tubular dysfunction and stones despite later biochemical control.

09Monitoring and follow-upTreatment response, safety checks and longer-term review.
  • Record hepatic, neurological, psychiatric, speech, swallowing and functional status with the same measures over time, especially during the first months of a new chelator.
  • Trend liver tests, INR, albumin, full blood count, renal function and urinalysis at the product-specific interval and urgently after toxicity symptoms.
  • Use twenty-four-hour urinary copper and other specialist copper measures in relation to treatment type, timing and adherence; do not compare unlike sampling conditions casually.
  • Review exact product, salt, strength, food separation, supplements and pharmacy supply at every visit because formulation confusion can destabilise control.
  • For cirrhosis continue portal, nutrition and HCC surveillance and reassess transplant candidacy after first decompensation or recurrent loss of control.
  • Maintain lifelong family, pregnancy and transition documentation and actively follow missed appointments because silent non-adherence can precede catastrophic relapse.
10Special situationsVariants, exceptions and circumstances that change the usual approach.

Total copper can look low

Reduced caeruloplasmin lowers measured total serum copper even when toxic non-bound copper is driving hepatic or neurological injury.

A ring can be absent

Kayser-Fleischer rings are strongly supportive when present but their absence is insufficient to reject a hepatic presentation.

Acute failure distorts the textbook

Caeruloplasmin, urine copper and liver tests behave atypically in fulminant disease, making the haemolytic pattern and transplant urgency more important than a perfect score.

Trientine is not one product

Different salts express dose differently and require deliberate conversion; a pharmacy substitution can become a clinical dosing error.

Lifelong means through pregnancy

Unsupervised cessation risks maternal hepatic deterioration, so pregnancy planning focuses on monitored adjustment rather than a drug-free interval.

11Common pitfallsFrequent interpretation and management errors.
  1. 01

    Excluding Wilson disease from one normal caeruloplasmin or absent Kayser-Fleischer ring.

  2. 02

    Waiting for genetic confirmation before contacting a transplant centre in haemolytic acute liver failure.

  3. 03

    Interpreting low total serum copper as evidence that tissue copper overload is impossible.

  4. 04

    Switching between trientine salts at the same milligram number without specialist pharmacy conversion.

  5. 05

    Escalating chelation rapidly in neurological disease without monitoring for paradoxical functional worsening.

  6. 06

    Stopping lifelong anti-copper treatment after biochemical improvement or during pregnancy without expert planning.

Practice

Two practice questions

Question 1 of 20 correct
Gastroenterology and hepatologyOriginal SBA

Testing suspected Wilson disease

A 19-year-old has unexplained hepatitis, a new tremor and a low caeruloplasmin result. Which complete diagnostic approach is most appropriate now?

Sources and review status5 sources · checked 27 Aug 2026 · clinical review pending
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

Authoring stateComplete draftClinical stateAwaiting reviewJurisdictionUnited Kingdom